Mechanistic studies suggested that fisetin not only downregulates VEGFR1, p-ERK1/2, p38 and pJNK signaling pathways to hinder the progression of liver cancer, but also induces apoptosis of liver cancer cells by activating caspase-3 (Liu et al., 2017). This evidence concerns the gene MAPK3 and liver cancer.